Stay updated with breaking news from Genomic Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dublin, Feb. 08, 2021 (GLOBE NEWSWIRE) -- The "Global Genomic Data Analysis and Interpretation Market: Focus on Products, Genomic Platforms,...
National Counterintelligence and Security Center (NCSC) issued the warning in a fact sheet released on Feb. 1. The document said that China’s acquisition of sensitive healthcare and genetic data – both through legal and illegal means – threatens U.S. privacy and security. According to the fact sheet, the Chinese regime utilized investments in American biotechnology firms and partnerships with hospitals and universities to obtain sensitive data. With vast amount of American citizens’ genetic information, China can overtake the U.S. in the field of biotechnology or weaponize this inform...
Global Genomic Data Analysis and Interpretation Market to Reach $2. 10 Billion by 2030. Market Report Coverage - Genomic Data Analysis and Interpretation.New York, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Genomic Data Analysis and Interpretation Market: Focus on Products, Genomic Platforms, Applications, End Users, Country Data (15 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030" - https://www.reportlinker.com/p06010555/?utm_source=GNW Market Segmentation• Product – Software and Services (Lic...
Brooks Announces GENEWIZ Selected as Genome Characterization Center by the National Cancer Institute News provided by Share this article Share this article CHELMSFORD, Mass., Jan. 12, 2021 /PRNewswire/ -- Brooks Automation, Inc. (Nasdaq:BRKS) announced today that GENEWIZ, the Company's genomics analysis business, has been awarded one of six Genome Characterization Center Indefinite Delivery Indefinite Quantity (IDIQ) contracts from the National Cancer Institute (NCI). The NCI, the nation's leader in cancer research and part of the National Institutes of Health (NIH), chose GENEWIZ to pro...
email article SAN ANTONIO -- An online tool, which incorporates clinicopathological data and the results of the 21-gene recurrent score, was able to estimate risk of distant recurrence (DR) and adjuvant chemotherapy benefit in certain patients with breast cancer, a researcher reported. The RSClin tool integrates the recurrence score (RS) with tumor grade, tumor size, and age using a patient-specific meta-analysis that included 10,004 women with hormone receptor-positive, HER2-negative, and node-negative breast cancer who received endocrine therapy alone in the B-14 trial, or with chem...